- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT07943000
Phase 0 Study to Define the Effect of Low Dose Ethacrynic Acid on Total Glutathione (GSH) Levels and Glutathione S-transferase (GST) Activity (TRACer)
This study will examine how low doses of ethacrynic acid affect substances in the blood involved in protecting cells from damage. These substances include glutathione and an enzyme called glutathione S-transferase. The findings may help researchers plan future cancer studies.
Ethacrynic acid is an approved prescription medicine used to treat fluid buildup. Its use in this study to change these blood markers in healthy adults is experimental.
Up to 40 healthy adults will participate. The first group will receive a 25 mg oral dose at each of two visits approximately one week apart. If results meet the study criteria, a second group will receive 12.5 mg at each visit.
Participants will provide blood samples before and approximately 90 minutes after each dose. Study staff will ask about symptoms during the visits and during a final telephone call approximately one week after the second dose. Participation will last approximately two weeks.
Descripción general del estudio
Estado
Condiciones
Intervención / Tratamiento
Descripción detallada
Glutathione (GSH) and glutathione S-transferases (GSTs) contribute to cellular protection against oxidative stress and the detoxification of electrophilic compounds. In cancer cells, increased activity of these systems may contribute to resistance to anticancer therapies. Ethacrynic acid, an approved loop diuretic, can inhibit GST activity and react with GSH to form conjugates, potentially reducing cellular GSH availability. Whether low oral doses produce measurable pharmacodynamic effects in healthy adults remains uncertain.
TRACer will investigate these biological effects in healthy volunteers to reduce confounding from malignancy, prior cancer treatment, organ dysfunction, and concurrent prescription medications. The study uses paired measurements before and after drug administration, allowing each participant to serve as their own control. Repeating administration approximately one week later will help characterize the consistency of the pharmacodynamic response. Comparison of pre-dose measurements across visits will also provide information about whether changes persist between administrations.
The sequential cohort design evaluates the higher dose first. Enrollment into the lower-dose cohort will occur only if the initial cohort meets the protocol-specified criterion for biological activity. This approach is intended to determine whether target engagement can be demonstrated at doses below those commonly used to produce diuresis.
Peripheral blood mononuclear cells provide accessible material for assessing GST activity. Measurements of total GSH in plasma and erythrocytes provide complementary information about glutathione pools in different blood compartments. Coded specimens will undergo research laboratory analysis at the University of Vermont. These assays will not guide clinical care, and individual research results will not be returned to participants.
The study is intended to inform the design of subsequent investigations of ethacrynic acid as a potential adjunct to cancer therapy. It does not evaluate antitumor activity, and no direct clinical benefit to participants is anticipated.
Tipo de estudio
Inscripción (Estimado)
Fase
- Fase temprana 1
Contactos y Ubicaciones
Estudio Contacto
- Nombre: Randall Holcombe, MD, MBA
- Número de teléfono: 802-656-2207
- Correo electrónico: Randall.holcombe@med.uvm.edu
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion Criteria:
- Healthy volunteer without acute or chronic illness.
- Age 18 years or older.
- Willing and able to provide informed consent.
Exclusion Criteria:
- Ongoing use of any prescription medication.
- Known hypersensitivity to ethacrynic acid.
- Known renal or hepatic impairment.
- Current pregnancy or breastfeeding.
- Current tinnitus, hearing impairment, or other significant hearing disorder.
- Baseline systolic blood pressure of 100 mm Hg or less.
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Ciencia básica
- Asignación: No aleatorizado
- Modelo Intervencionista: Asignación de un solo grupo
- Enmascaramiento: Ninguno (etiqueta abierta)
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
|---|---|
|
Experimental: Ethacrynic Acid 25 mg
Approximately 20 participants will receive ethacrynic acid 25 mg orally at each of two dosing visits separated by one week ±1 day. |
Oral ethacrynic acid administered at 25 mg or 12.5 mg per dose, according to cohort, on two occasions approximately one week apart.
Otros nombres:
|
|
Experimental: Ethacrynic Acid 12.5 mg
If the first cohort meets the protocol-specified biological activity criterion, approximately 20 additional participants will receive ethacrynic acid 12.5 mg orally at each of two dosing visits separated by one week ±1 day. |
Oral ethacrynic acid administered at 25 mg or 12.5 mg per dose, according to cohort, on two occasions approximately one week apart.
Otros nombres:
|
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Change in Peripheral Blood Mononuclear Cell GST Activity
Periodo de tiempo: Before dosing and 90 ±15 minutes after dosing at the first visit and the second visit approximately one week later
|
Change in glutathione S-transferase activity from the pre-dose measurement to the post-dose measurement, evaluated separately for each dosing visit. |
Before dosing and 90 ±15 minutes after dosing at the first visit and the second visit approximately one week later
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Change in Plasma Total Glutathione
Periodo de tiempo: Before dosing and 90 ±15 minutes after dosing at both dosing visits
|
Change in plasma total glutathione from the pre-dose measurement to the post-dose measurement, evaluated separately for each dosing visit. |
Before dosing and 90 ±15 minutes after dosing at both dosing visits
|
|
Change in Erythrocyte Total Glutathione
Periodo de tiempo: Before dosing and 90 ±15 minutes after dosing at both dosing visits
|
Change in erythrocyte total glutathione from the pre-dose measurement to the post-dose measurement, evaluated separately for each dosing visit. |
Before dosing and 90 ±15 minutes after dosing at both dosing visits
|
|
Number of Participants With Adverse Events
Periodo de tiempo: From the first dosing visit through the final telephone assessment, one week ±2 days after the second dosing visit, approximately two weeks
|
Number of participants experiencing adverse events, summarized by event type, severity, and relatedness. Severity will be graded using the protocol's CTCAE criteria. |
From the first dosing visit through the final telephone assessment, one week ±2 days after the second dosing visit, approximately two weeks
|
Colaboradores e Investigadores
Patrocinador
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Estimado)
Finalización primaria (Estimado)
Finalización del estudio (Estimado)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Términos MeSH relevantes adicionales
Otros números de identificación del estudio
- UVMCC2609
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
producto fabricado y exportado desde los EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .